Studies have shown that expression of LMP1 and LMP2A significantly affects the prognosis of lymphoproliferative disorders, and in some cases, can lead to an increased risk of a negative disease outcome [10,11,12,13]. Here, PDLIM7 is linked to lymphoproliferative syndrome.